ARFI ultrasound for in vivo hemostasis assessment postcardiac catheterization, part I: preclinical studies

Russell H Behler1, Mallory R Scola, Timothy C Nichols

  • 1Joint Department of Biomedical Engineering, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Ultrasonic Imaging
|September 24, 2009
PubMed

Insights

Acoustic Radiation Force Impulse (ARFI) ultrasound can un-blind the assessment of hemostasis at femoral artery puncture sites. This novel imaging technique shows promise for improving patient safety after cardiovascular procedures.

Area of Science:

  • Cardiovascular Imaging
  • Medical Ultrasound Technology
  • Interventional Cardiology

Background:

  • Percutaneous coronary catheterization frequently uses femoral artery access.
  • Inadequate hemostasis at femoral puncture sites can lead to severe complications.
  • Current hemostasis assessment is indirect and can be unreliable.

Purpose of the Study:

  • To investigate Acoustic Radiation Force Impulse (ARFI) ultrasound for assessing hemostasis after femoral artery puncture.
  • To establish proof of concept for ARFI ultrasound in a preclinical model.

Main Methods:

  • In vivo ARFI ultrasound imaging was performed in canine models of femoral artery puncture.
  • ARFI-induced displacements were measured above arteriotomies post-needle removal.
  • Changes in displacement magnitude over time were analyzed.

Main Results:

  • Large ARFI displacements (3.5 to >5.0 microm) were observed initially, indicative of extravasated blood.
  • Displacements decreased significantly (to ~2 microm) over time, suggesting successful hemostasis.
  • These findings provide preclinical validation for ARFI's utility in hemostasis assessment.

Conclusions:

  • ARFI ultrasound can effectively visualize and quantify changes associated with hemostasis at femoral artery puncture sites.
  • This imaging modality offers a potential method to "un-blind" hemostasis assessment, improving procedural safety.
  • The study justifies further investigation in human clinical trials.